Arcellx, Inc.
ACLX
Ранг среди акций
#2787
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Цена акции
$115.07
Последняя синхронизация: 2026-05-15
Рыночная капитализация
$6.73B
Изменение (1 день)
0.00%
Изменение (1 год)
32.61%
Страна
US
Торговля Arcellx, Inc. (ACLX)
Категория
Healthcare
Коэффициент P/S для Arcellx, Inc. (ACLX)
Коэффициент P/S на October 2026 TTM: 475.55
Согласно последним финансовым отчетам и цене акций Arcellx, Inc., текущий коэффициент P/S (TTM) составляет 475.55. В конце 2023 он составлял 24.18.
История P/S для Arcellx, Inc. с 2018 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2026 (TTM) | 475.55 | 1,149.47% |
| 2024 | 38.06 | 57.41% |
| 2023 | 24.18 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | -97.89% |
US
|
|
| 40.55 | -91.47% |
US
|
|
| 3.96 | -99.17% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -97.87% |
NL
|
